Mechanisms of Disease: antiphospholipid antibodies—from clinical association to pathologic mechanism
Authors:
- 19 February 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 4 (4) , 192-199
Abstract
The discovery that antiphospholipid antibodies recognize plasma proteins that bind to phospholipids rather than recognizing phospholipids themselves has been a major advance in research into antiphospholipid syndrome (APS). It is now established that β2-glycoprotein I (β2 GPI) is the most important antigen for antiphospholipid antibodies. However, the possible pathologic mechanism is still much debated. This is mainly because not all patients with anti-β2 GPI antibodies show clinical symptoms that are related to APS. Several reports indicate that anti-β2 GPI antibodies with lupus anticoagulant (LA) activity are clinically of much importance. Most patients with LA caused by anti-β2 GPI antibodies suffer from thrombosis as a result of recognition of the first domain of β2 GPI by these antibodies. In the search for a pathologic mechanism that might explain the high occurrence of thrombosis in patients with anti-domain I antibodies (LA-causing anti-β2 GPI antibodies), it was found that these antibodies show increased resistance to the anticoagulant activity of annexin A5. We have shown that the same population of antibodies also displays increased resistance to activated protein C. Owing to the diversity of clinical symptoms related to APS, it is likely that other pathologic mechanisms also contribute to the occurrence of APS-related symptoms.Keywords
This publication has 43 references indexed in Scilit:
- Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein CBlood Coagulation & Fibrinolysis, 2008
- β2-Glycoprotein I inhibits von Willebrand factor–dependent platelet adhesion and aggregationBlood, 2007
- Platelets express three different splice variants of ApoER2 that are all involved in signalingJournal of Thrombosis and Haemostasis, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Acquired Activated Protein C Resistance Associated with IgG Antibodies against β2-Glycoprotein I and Prothrombin as a Strong Risk Factor for Venous ThromboembolismClinical Chemistry, 2005
- Antibody profiles for the diagnosis of antiphospholipid syndromeThrombosis and Haemostasis, 2005
- Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndromeBlood, 2004
- β2-Glycoprotein I, the playmaker of the antiphospholipid syndromeClinical Immunology, 2004
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactorsJournal of Chronic Diseases, 1955